Prior studies also evaluated the cost-effectiveness of pembrolizumab (5, 45) or cemiplimab (46) monotherapy for patients with advanced NSCLC with high PD-L1 expression compared to platinum-based chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.